Why the study?
Does the measurement of serum Activin A improve the assessment of insulin resistance and cardiovascular risk in prediabetics?
Does the measurement of serum Activin A improve the assessment of insulin resistance and cardiovascular risk in prediabetics?
Activin A may serve as a useful biomarker for assessing insulin resistance and cardiovascular risk in prediabetic patients, potentially guiding preventive therapies.
Activin A may aid risk stratification in prediabetes; leaves open prospective validation before clinical adoption.
Activin A, if combined with other atherosclerotic markers, might improve the assessment of insulin resistance and cardiovascular risk in prediabetics and lead to focus on lifestyle modifications and preventive medical therapy, thereby contributing to the prevention of CVD-related mortality and morbidity in these patients.
No takes yet. Share an insight, caveat, or question.
Chauhan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: